Historical Valuation
Verrica Pharmaceuticals Inc (VRCA) is now in the Undervalued zone, suggesting that its current forward PS ratio of 5.43 is considered Undervalued compared with the five-year average of -4.21. The fair price of Verrica Pharmaceuticals Inc (VRCA) is between 9.51 to 12.68 according to relative valuation methord. Compared to the current price of 7.95 USD , Verrica Pharmaceuticals Inc is Undervalued By 16.44%.
Relative Value
Fair Zone
9.51-12.68
Current Price：7.95
16.44%
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Verrica Pharmaceuticals Inc (VRCA) has a current Price-to-Book (P/B) ratio of -4.62. Compared to its 3-year average P/B ratio of 18.42 , the current P/B ratio is approximately -125.09% higher. Relative to its 5-year average P/B ratio of 13.48, the current P/B ratio is about -134.29% higher. Verrica Pharmaceuticals Inc (VRCA) has a Forward Free Cash Flow (FCF) yield of approximately -21.93%. Compared to its 3-year average FCF yield of -48.52%, the current FCF yield is approximately -54.81% lower. Relative to its 5-year average FCF yield of -35.01% , the current FCF yield is about -37.37% lower.
P/B
Median3y
18.42
Median5y
13.48
FCF Yield
Median3y
-48.52
Median5y
-35.01
Competitors Valuation Multiple
AI Analysis for VRCA
The average P/S ratio for VRCA competitors is 23.53, providing a benchmark for relative valuation. Verrica Pharmaceuticals Inc Corp (VRCA.O) exhibits a P/S ratio of 5.43, which is -76.9% above the industry average. Given its robust revenue growth of -905.39%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for VRCA
1Y
3Y
5Y
Market capitalization of VRCA increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of VRCA in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is VRCA currently overvalued or undervalued?
Verrica Pharmaceuticals Inc (VRCA) is now in the Undervalued zone, suggesting that its current forward PS ratio of 5.43 is considered Undervalued compared with the five-year average of -4.21. The fair price of Verrica Pharmaceuticals Inc (VRCA) is between 9.51 to 12.68 according to relative valuation methord. Compared to the current price of 7.95 USD , Verrica Pharmaceuticals Inc is Undervalued By 16.44% .
What is Verrica Pharmaceuticals Inc (VRCA) fair value?
VRCA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Verrica Pharmaceuticals Inc (VRCA) is between 9.51 to 12.68 according to relative valuation methord.
How does VRCA's valuation metrics compare to the industry average?
The average P/S ratio for VRCA's competitors is 23.53, providing a benchmark for relative valuation. Verrica Pharmaceuticals Inc Corp (VRCA) exhibits a P/S ratio of 5.43, which is -76.90% above the industry average. Given its robust revenue growth of -905.39%, this premium appears unsustainable.
What is the current P/B ratio for Verrica Pharmaceuticals Inc (VRCA) as of Jan 10 2026?
As of Jan 10 2026, Verrica Pharmaceuticals Inc (VRCA) has a P/B ratio of -4.62. This indicates that the market values VRCA at -4.62 times its book value.
What is the current FCF Yield for Verrica Pharmaceuticals Inc (VRCA) as of Jan 10 2026?
As of Jan 10 2026, Verrica Pharmaceuticals Inc (VRCA) has a FCF Yield of -21.93%. This means that for every dollar of Verrica Pharmaceuticals Inc’s market capitalization, the company generates -21.93 cents in free cash flow.
What is the current Forward P/E ratio for Verrica Pharmaceuticals Inc (VRCA) as of Jan 10 2026?
As of Jan 10 2026, Verrica Pharmaceuticals Inc (VRCA) has a Forward P/E ratio of -4.11. This means the market is willing to pay $-4.11 for every dollar of Verrica Pharmaceuticals Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Verrica Pharmaceuticals Inc (VRCA) as of Jan 10 2026?
As of Jan 10 2026, Verrica Pharmaceuticals Inc (VRCA) has a Forward P/S ratio of 5.43. This means the market is valuing VRCA at $5.43 for every dollar of expected revenue over the next 12 months.